Thanks, and joining focus business our recovery want second my thank everyone, on Julie. our of Good today. state quarter and afternoon, I for on the us of you launch. the comments current to PDN progress results, our and
continues that results guidance the forward staffing issues the guidance. experience in more that the us will above slower moving to originally we procedures. progress were to cover QX results, the overall range. was lingering customer revenue growth impress we Following by of these of the in QX, our facility PDN the we adjusted and continue Despite line. continue EBITDA high of end and results Rod my our that in to move comments, Overall, we our evidenced permanent and impact though business believe least serve specifics to revenue believe to a many recovery, our elements our continue still durable of have And slow overall encouraging implant is the and be of path pace we more patient throughput, date. than anticipated, down particularly term. of near may had market of recovery uneven at There that been that to
was and patient of made in continue growth progress the the referrals extremely encouraged XXXX. pre-COVID XX% to in the are also ahead revenue U.S. PDN particularly launch We're our in pace progress of with have payers. with drive continued pleased which as We our our quarter, we by
Boston to we a Scientific. in non-surgical patients. to litigations treat Monday, also And our reach with We to settlement early some as pain believe finally, able we build momentum we've on with indication announced begun were back our
we that kilohertz, where all X.X best-in-class license and a asserted we current provider to of competing. a current Now which embodied The consider X.X litigations, patents, agreement of to will all products, for covenant and Nevro as not a in the to settlement in high-frequency granted 'XX. which we've compromised release of our HFX part The of XX to Boston payment to sue of Boston features dismissal core November. exclusive the reverse the paresthesia-free was that way the resulting was million Scientific Monday's was $XX any jury receive Nevro in Boston Scientific the of The kilohertz. any awarded quarter not a release cash therapy to verdict the of settlement, Please therapy. filed licensed XXX of Delaware liability frequencies Nevro remain XXXX. limited IP, We third note has by is K what impact unique been to below allows Boston press ranges last terms $XX Nevro a has P&L we to beyond to release third loss stated are or Scientific that million confidential. $XXX from X-K the quarter Scientific $XX million in is accounting accrued The our million in in be what license positive
we're So able beyond behind us. been pleased to But publicly be your many disclosed. not has of to we'll questions answer have what of already course, this
And growth. total in particularly expect normal to at encouraging to Despite compared XX% we compared quarter, capacity compared X% impacts, actual to QX QX trial year-over-year of the X% QX, XXXX, a the late trial Now see procedures year XX% to while quarter. increased XXXX. compared the the in implant we by continue now permanent for procedure seasonality quarter. year look activity staffing and shortage procedures and we the encouraged of QX procedures I'm U.S. in to trial while in prior and increased saw prior increase let's take
on Lingering still Based this to intact. the patient and trend the that pressure return and attractive underlying opportunity growth of importantly, to however, moving to growth staffing us trial issues, later the the rates as market trial is SCS and revenue believe Our scheduling more addressable to on we willingness the of to is data the positioned the attractive the of procedures market rates fundamentals put refill. funnel in confirms in engage procedures. is improving year toward remain and for procedures, continues SCS recovery
it's to therefore, in includes Now procedures, which perm curve trial particularly serves trials procedures, or our patient or while revenues. conversion evident perm time TXP this to perms to to the lengthen average trial and convert
planned, XXXX. thinking second quarter We about In particularly year has trial meantime, at how performance expect to even this much somewhat we and revenues. to lengthened improve and conversion a we're improve, later third into to curve than half continues with the slower this do pace though albeit this
guidance trial guidance In updated to of completed us at hundreds if back takes data those reflects to with getting remember second was patients had surveys In higher constant account, research SCS physicians July, though in us discuss our physicians it's volumes Rod last that that Our X% compared staffing some. will monthly procedure having the was in more planned. growth team not quite implanting last as originally to confirms concerns we XX% impact work are The primary survey also financial months physician XX% the this later few our revised as important that for the and volume half revenue general, some with market total year this yet pace the not still though well. research, of year, patients, by detail better, into currency basis. and noted an SCS levels. recent market of pain reviewed In claims chronic a though challenges, XXXX to on dynamic told cited on things up that we
For July, efficiency which therefore, less experience patient experienced XX% as office staff, importantly, staffing told impact procedure OR and and scheduling, of the turnover scheduling such overall and throughput. office to month physicians us office continue of they newer, challenges
influx of physicians the of due the XX% delayed believe patients drivers recovery. who new market treatment seeing pandemic, noted to also be who they're will Fortunately, they of an
had mentioned Now consistent ago. a of patients providers, our received pain sensitivity research, which expressed surprisingly, deductibles. with moment and we from feedback they the Not us higher appointments in in scheduling they've co-pays difficulty I physicians, around is, patient course, with also told
surprised though the procedure pain in their current doctor patients certainly said year this seeing always pain and has the six a not in it been are hear this XX Encouragingly, the of they last say than year. of Now months, canceled case, more the XX% end to have environment. or this we to patients last were plan procedure delayed who before they
up procedures X.X% were and volumes XXXX. are the five hand, the perm the to in compared up period 'XX in compared the period last turning the months data trials same that to the SCS first prior compared with total trends claims five year, U.S. down of the on Based procedures, months for the the X% still and in procedures U.S. up versus same market period same on were but survey Now permanent are first actual in of other perm XXXX. to data implant XX% year X% for for work. latest consistent Nevro actual 'XX third-party claims for U.S. procedure to
of more are accurately Now share really number impacted indication including implanted these of numbers by and products data things, procedural be are are timing of are patients particularly there a indicate growth shipments, being revenue important because numbers while in these actually can growth good what trends.
procedure compared year growth and 'XX, by five XXX basis first respectively. and outpaced months the to points, rate For Nevro market the X,XXX 'XX of
So procedures win revenues. we're continue are Remember, confident our these not actual that reported to competitively. we
example. comparables from some the not things So for like destocking are remember, that XXXX prior year impacted by issues of might you period
now and physicians our of the to therapy. we're pleased increased patient seeing. educated we're the Regarding and what and passed we've referring our launch, awareness one-year for thousands really with driven access PDN with and performance, patients We've significantly mark commercial
that total describing. During trials the improved XX% compared quarter. approximately trials they grew in volume, up in XX% trial of been total from PDN volume U.S. trial the of represented despite the sequentially market U.S. QX throughout course issues of our to I've the XX% U.S. and the quarter, lingering QX PDN
all procedures PDN permanent it that increase to our now contribution, revenue resulted XX% the total number trained, PDN approximately compared and and of of million prior our planned the XX% in territories, worldwide in their been As that's sequentially of bringing of procedures, relates referral and have in they're reps reps expansion $X PDN We've implant additional These $XX territories. XX. an quarter. PDN million approximately represented to completed total to now
on implanting to these sales and awareness our our Our calling for our team their in patients. to therapy for pain interest generate continues out communities existing specialists physicians local drive reach physicians to among SCS referring
XX% nearly pain from grow. doubled before more referrals nearly last patient they our are proactively local the physicians or a in implanting and end when of has At of outreach As pain become marketing physicians and June, continues PDN that a say of we seen approval, of mentioned we've to and PDN rapidly our number have call, that meaningful share our volume. physicians percentage received their successes, one monthly initiate patient PDN really can the patient seeking referrals, individual
and campaign physicians, percentage we implanting members as demand from qualified volumes. funnel, to PDN as and in monthly HFX is continue for Further XX% coming quickly sales For and The efforts up PDN patient and of educate our patient at order continue to these our we of as XX% we've top strengthen look to growing activate seen our leads. team much trial direct-to-consumer example, DTC invest patient their that to if very grow coaches some to in leads. can our procedures acquire PDN the
we reference As PDN Scientific to XX% the other XX-month trial leads. and share landmark excited June, pain achieved treatment this a were in the safety, to outcomes can time, U.S. for patient of Sessions DTC arm year's the month these At of procedures ADA durability our clearly XX of results for continue June, of the from the and came first trial, from be that K in our of with or HFX consistency which demonstrate SENZA-PDN PDN. relief point
improvement neurological been SCS has treating for neuropathy, the to SCS of research studied. prior related the diabetic looked first is time benefit this after pain that has While at
patients. important XX% who sleep significant we opportunity to in reduction in traditional an demonstrate Our Proceedings relief and difference. such have Mayo expand other symptom this data XX% also results in of these patients Clinic life sleep, with treatment No XX-month improvement health-related unable positive option that to improvement, including These with patients, and treatments of life showed that clinically pleased mood health-related pain metrics with SENZA-PDN treating demonstrated a a trial, average less SCS interference find X to quality in was quality average significantly the minimal in from believe PDN there's activities. the results innovative PDN, complete low-frequency times July. a neurological And are disturbance any We're outcomes published results in improvement early which the quality options. daily important included of several the in life
XX XX-month SCS kilohertz life health-related to that treatment that overall the resulted higher clinically times of X.X than a considered quality was in Importantly, improvement X.X in difference important. times is
to to at that complete thereafter. NANS with our a lives momentum of coverage up submit Evidence we engagement We be of 'XX of coverage, area PDN We the and as which Pacific now clinical represent submitted of our them Street's Illinois, available of to XX% Oklahoma recent These publish Combined, to plans international PDN number included updates decisions addressable with for covered XX% Blue Evidence QX, on our arm. of plan Insurers data from as XX were they're just XX-month Cross but incorporated explicitly health and commercially presentation Texas. Alabama, these efforts. year. is expect the evidence proactive payer past in Idaho, to critical as Northwest, can quarter. data in January. the PDN. Street, Shield from are policy PDN, evidence-based SCS January updates update part the population and soon In our the as to we assessment in Remember from of million or BCBS tech review nearly U.S. coverage providers the New BCBS announced Montana, for this Blue the important, among Mexico, BCBS in cover these during Hawaii, covered June recently to this policy the nearly -- That's update a insured start formal U.S. attribute under updates
including prior appeal level patient payers the not a the who We of coverage with process and through coverage a case-by-case policy. denials, have of a see continue to basis on high PDN do auth payer specific
$XX XX% our own from in of our Based PDN that cumulative our at to sales guidance a this $XX the now rate XX%, cases about million approval climbed PDN through the the year, million 'XX includes million of June as beginning year. up $XX at have from to original end million the guidance half of on year. For of the performance come first our contribution of access to the our from $XX group, strong PDN, of beginning up
annually when is the treatment This million available we've are who management limited of in Moving expand this back this large to and after as both trials pain sequential population. we X.X We users. from who not have began to current trials are activities these medical and non-surgical with FDA in candidates indication underpenetrated approval therapy discussed, a now surgery options for commercial receiving new patients January, in less market, successful. growth and invasive not during QX access to NSBP with for approximately HFX and therapy coming saw U.S.
has are patients, this about made population currently our receiving up NSBP historically only therapy. this of large X% of patient While around XX%
the at education are Our not identification already these and candidates surgery. pain practices for on and had have strategy prior who patients not of who existing surgery focuses
and So customers far, our looking they're for are these patients and to receptive outreach to actively treat. excited
hope to database XX, over which We before leveraging superior the significant will to market continue will cloud delivery end of a platform. first approval, HFX of to of the This receive We our million 'XX. our clinical step FDA once therapy. release in we our next-generation come in XX high-frequency inform the intelligently begin limited XXX plan we the for launch system points also be data the new product prepare and
at detail and this the but of Now we'll a platform about it and time, that excited power really we're time. for more us over do and what can our provide immediately lot patients
with more core over pass for results I'll So hoped, will recovery on a what are start second as in SCS in that, markets in to our seeing we slowly emerging of guidance. further bit the the our made quarter. well call the while PDN believe of we be closing, resolving continued details encouraging and last the quarter drivers. as our clearly, provide growth real of And And we on than years our in in progress businesses challenges Rod the and to excitement second cause we're couple our
